• Mashup Score: 1
    The Hazy Days of Summer - 2 year(s) ago

    An awareness that the air around you isn’t fit to breathe can be a uniquely alarming sensation. It is also likely to become more common.

    Source: The New Yorker
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ESchattner
      ESchattner

      When it comes to health, "wildfire smoke may be the most injurious form of air pollution..[It] has been linked to asthma and emphysema; Alzheimer’s and Parkinson’s; cancer and strokes; depression and suicide; miscarriages, premature births.." @DhruvKhullar https://t.co/wGNRAdnfgU

  • Mashup Score: 0
    The Hazy Days of Summer - 2 year(s) ago

    An awareness that the air around you isn’t fit to breathe can be a uniquely alarming sensation. It is also likely to become more common.

    Source: The New Yorker
    Categories: Healthcare Professionals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of DhruvKhullar
      DhruvKhullar

      Air quality in New York and the upper Midwest is worsening again. In this week’s @NewYorker, I write about wildfire smoke, air pollution, and the many hazards to our health. https://t.co/crohoWyXVG

  • Mashup Score: 1
    When Dying Patients Want Unproven Drugs - 2 year(s) ago

    Patient-advocacy groups mobilized to demand access to a controversial new drug called Relyvrio. But hasty approval comes at a cost.

    Source: The New Yorker
    Categories: Latest Headlines, Rare Disease
    Tweet Tweets with this article
    • Profile photo of alsadvocacy
      alsadvocacy

      Many advocacy issues in ALS Land are not simple. Solutions are not either black or white. This long article demonstrates that it's complicated. It's worth reading carefully. https://t.co/4Au9FHSorN

  • Mashup Score: 11
    When Dying Patients Want Unproven Drugs - 2 year(s) ago

    Patient-advocacy groups mobilized to demand access to a controversial new drug called Relyvrio. But hasty approval comes at a cost.

    Source: The New Yorker
    Categories: HIV/AIDS, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of gregggonsalves
      gregggonsalves

      Making FDA approval your only goal even with poor evidence of effectiveness incentivizes more of the same. Asking for rigorous evidence as part of approval process sets the bar higher. Otherwise it’s how low can you go for the next drug down the line. https://t.co/4cVUc0FqGH

    • Profile photo of gregggonsalves
      gregggonsalves

      It’s simply not true that all patient advocates just want access to experimental drugs. We also want to know if they work. This requires a commitment to getting the evidence. These are not incompatible goals. We need access AND answers. https://t.co/4cVUc0FqGH

Load More